PARIS, May 14, 2025--(BUSINESS WIRE)--BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, announced today it has received 510(k) clearance ...
BrightHeart has gained a further 510(k) clearance from the US Food and Drug Administration (FDA) for its AI-based prenatal congenital heart defect (CHD) screening platform. Building on the initial FDA ...
PARIS--(BUSINESS WIRE)--BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and ...
BrightHeart has raised €11m ($12.8m) in funding to advance commercialisation efforts for its artificial intelligence (AI)-based prenatal congenital heart defect (CHD) screening platform. The French ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results